Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Kelindi | INDUSTRY |
| Centre National de la Recherche Scientifique, France | OTHER |
| Hospital of Tours | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Anosmia is a symptom present in 40 to 80% of patients and usually only lasts 1 to 2 weeks. However, in nearly one in five patients, it can last beyond or even several months with consequences in terms of undernutrition and depression. However, olfactory rehabilitation is a technique validated in post-infectious anosmia since 2014 and recommended by international learned societies to accelerate recovery with nearly 63% improvement in anosmia In the context of the health crisis linked to the coronavirus, approximately 1 million French people will have persistent anosmia following an infection with COVID-19. A web-application to support the olfactory coaching of anosmic patients and help with follow-up seems relevant to promote recovery and the proper conduct of this coaching.
covidanosmie.fr is a web application dedicated to olfactory rehabilitation, accessible free of charge.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| users | Users of web-application |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Web-application | Device | support for olfactory coaching consisting of the inhalation of fragrant essential oils. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of the rate of patients presenting an improvement in their anosmia | Number of patients with an improvement in anosmia (increase of at least 1 point on the visual analogue scale 0-10) on the number of users | 16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of the time until recovery of at least 1point in 10 (Visual Analog Scale) from anosmia, | Time between the date of first use of the application and the date of recovery of at least one point of anosmia | 16 weeks |
| Assessment of the duration of anosmia |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All users of the application who have not objected to the use of their data
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Fabrice DENIS, MD | Weprom | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ILC | Le Mans | 72000 | France |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D000086582 | Anosmia |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Time between the date of diagnosis or onset of anosmia and the date of final recovery |
| 16 weeks |
| Evaluation of the recovery of at least one point in 10 (Visual Analog Scale) depending on the oils | Evolution of the VAS according to the different oils, proportion of patients with an increase of at least 1 point in anosmia on a visual analog scale (from 0 no smell to 10 normal smell) of each oil | 16 weeks |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000857 | Olfaction Disorders |
| D012678 | Sensation Disorders |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |